香港六合彩中特网

Researchers are investigating the safety and effectiveness of remdesivir as well as evaluating the optimal dosing and duration of the drug 鈥� with one study involving patients with moderate symptoms, and one study involving patients with severe COVID-19.

In the 鈥渕oderate COVID鈥� study, inpatients who do not require oxygen are randomised to receive the drug intravenously for five days or 10 days or receive the usual standard of care, and their outcomes will be assessed.

The 鈥渟evere COVID鈥� study has completed the phase which compared different treatment durations, and is now at the phase where patients who require oxygen are all given the drug intravenously for 10 days, and monitored for outcomes and any potential side effects of the treatment

Pharmaceutical company Gilead are sponsoring the studies, which began in the United States and China. Around 2,400 patients worldwide are expected to take part in the 鈥榮evere鈥� study, with 1,600 in the 鈥榤oderate鈥� study.

Gilead鈥檚 lab testing has demonstrated that remdesivir is active against the SARS-CoV-2 virus that causes COVID-19. Prior to the trials for COVID-19, 500 people had already taken the drug and no safety issues have been identified so far.

Dr Mike Brown, who is leading the portion of the studies taking place at 香港六合彩中特网H, said: 鈥淓vidence so far suggests that remdesivir is a safe drug,聽but we don鈥檛 yet know how effective it will be in patients. We also don鈥檛 know what the optimal duration of therapy will be, so we want to identify the minimum duration that will be effective. In the race against time we find ourselves in, we hope to be able to show that remdesivir is effective in Covid-19 and in which stage in a patient鈥檚 illness antivirals are useful.鈥�